scholarly journals Stereoelectroencephalography-Guided Radiofrequency Thermocoagulation (SEEG-Guided RF-TC) in Patients with Drug-Resistant Focal Epilepsy

2017 ◽  
Vol 3 (1) ◽  
pp. 40-47
Author(s):  
Chengwei Xu ◽  
Wenjing Zhou

For some patients with drug-resistant focal epilepsy, we usually select conventional surgical resection, which has brought better outcomes. However, others are not eligible for a conventional open surgical resection of the epileptogenic zone because of the proximity of a functional area or the implication of a larger epileptogenic network. Initially, stereoelectroencephalography (SEEG) exploration was a method of electroencephalography recording that was used in the presurgical evaluation of epileptic patients with complex epilepsy. Later, intracerebral electrodes used for SEEG were applied to produce radio frequency thermocoagulation (RF-TC) in epileptic patients. SEEG-guided RF-TC has produced some promising results, especially in the last dacade. Now, it has become popular as a palliative treatment to reduce seizure frequency in patients with drug-resistant focal epilepsy. This article presents a review of SEEG-guided RF-TC.

2012 ◽  
Vol 9 (3) ◽  
pp. 290-300 ◽  
Author(s):  
Massimo Cossu ◽  
Marco Schiariti ◽  
Stefano Francione ◽  
Dalila Fuschillo ◽  
Francesca Gozzo ◽  
...  

Object The authors report on the use of stereoelectroencephalography (stereo-EEG) in the presurgical electroclinical evaluation of infants and very young children with focal drug-resistant epilepsy. Methods Fifteen patients (9 girls and 6 boys, mean age 34.1 ± 7.3 months, range 21–45 months), potentially candidates to receive surgical treatment for their focal drug-resistant epilepsy, were evaluated using stereo-EEG recording for a detailed definition of the epileptogenic zone. Stereoelectroencephalography was indicated because neuroradiological (brain MRI) and video-EEG data failed to adequately localize the epileptogenic zone. Stereotactic placement of multicontact intracerebral electrodes was preceded by the acquisition of all pertinent anatomical information from structural and functional MRI and from brain angiography, enabling the accurate targeting of desired structures through avascular trajectories. Stereoelectroencephalography monitoring attempted to record habitual seizures; electrical stimulations were performed to induce seizures and for the functional mapping of eloquent areas. Stereoelectroencephalography-guided microsurgery, when indicated, pointed to removal of the epileptogenic zone and seizure control. Results Brain MRI revealed an anatomical lesion in 13 patients (lobar in 2 cases, multilobar or hemispheric in 11 cases) and was unremarkable in 2 patients. One patient underwent 2 stereo-EEG studies. The arrangement of the intracerebral electrodes was unilateral in all but 1 case. One patient died the day following electrode placement due to massive brain edema and profound hyponatremia of undetermined cause. In 8 cases intracerebral electrical stimulations allowed mapping of functionally critical areas; in 3 other cases that received purposeful placement of electrodes in presumably eloquent areas, no functional response was obtained. Of the 14 patients who completed stereo-EEG monitoring, 1 was excluded from surgery for multifocality of seizures and 13 underwent operations. Postoperatively, 2 patients exhibited an anticipated, permanent motor deficit, 3 experienced a transient motor deficit, and 2 experienced transient worsening of a preexisting motor deficit. Three patients developed a permanent homonymous hemianopia after posterior resections. Histological analysis revealed cortical malformations in 10 cases. Of the 10 patients with a postoperative follow-up of at least 12 months, 6 (60%) were seizure-free (Engel Class Ia), 2 (20%) experienced a significant reduction of seizures (Engel Class II), and 2 (20%) were unchanged (Engel Class IV). Conclusions The present study indicates that stereo-EEG plays a prominent role in the presurgical evaluation of focal epilepsies also in the first years of life and that it may offer a surgical option in particularly complex cases that would have scarcely benefitted from further medical treatment. Results of stereo-EEG–guided resective surgery were excellent, with 80% of patients exhibiting a substantial improvement in seizures. In consideration of the potentially life-threatening risks of major intracranial surgery in this specific age group, the authors recommend reserving stereo-EEG evaluations for infants with realistic chances of benefiting from surgery.


2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Ece Boran ◽  
Johannes Sarnthein ◽  
Niklaus Krayenbühl ◽  
Georgia Ramantani ◽  
Tommaso Fedele

Abstract High-frequency oscillations (HFO) are promising EEG biomarkers of epileptogenicity. While the evidence supporting their significance derives mainly from invasive recordings, recent studies have extended these observations to HFO recorded in the widely accessible scalp EEG. Here, we investigated whether scalp HFO in drug-resistant focal epilepsy correspond to epilepsy severity and how they are affected by surgical therapy. In eleven children with drug-resistant focal epilepsy that underwent epilepsy surgery, we prospectively recorded pre- and postsurgical scalp EEG with a custom-made low-noise amplifier (LNA). In four of these children, we also recorded intraoperative electrocorticography (ECoG). To detect clinically relevant HFO, we applied a previously validated automated detector. Scalp HFO rates showed a significant positive correlation with seizure frequency (R2 = 0.80, p < 0.001). Overall, scalp HFO rates were higher in patients with active epilepsy (19 recordings, p = 0.0066, PPV = 86%, NPV = 80%, accuracy = 84% CI [62% 94%]) and decreased following successful epilepsy surgery. The location of the highest HFO rates in scalp EEG matched the location of the highest HFO rates in ECoG. This study is the first step towards using non-invasively recorded scalp HFO to monitor disease severity in patients affected by epilepsy.


2019 ◽  
Vol 5 (3) ◽  
pp. 189-202
Author(s):  
Jianjun Bai ◽  
Wenjing Zhou ◽  
Haixiang Wang ◽  
Bingqing Zhang ◽  
Jiuluan Lin ◽  
...  

Stereoelectroencephalography (SEEG) has been widely used in the presurgical evaluation of patients with medically intractable epilepsy. In the past, SEEG was commonly used as a method for mapping and localizing the epileptogenic zone (EZ). Since 2004, several studies have been conducted to examine the effectiveness of SEEG-guided radiofrequency thermocoagulation (RF-TC) in treating refractory epilepsy. However, the seizure-free and responder rates varied greatly across studies. We aimed to analyze the outcome of 56 patients who were treated with SEEG-guided RF-TC to evaluate the effectiveness of this treatment. SEEG-guided RF-TC can be considered as a treatment for refractory epilepsy. However, due to its limited efficacy, SEEG-guided RF-TC might be regarded as a temporary treatment performed under SEEG rather than a promising treatment for refractory epilepsy.


2006 ◽  
Vol 117 (2) ◽  
pp. 341-347 ◽  
Author(s):  
F. Sebastiano ◽  
G. Di Gennaro ◽  
V. Esposito ◽  
A. Picardi ◽  
R. Morace ◽  
...  

2019 ◽  
Vol 12 (1) ◽  
pp. 141-147
Author(s):  
I. Gusti Ngurah Made Suwarba ◽  
Soetjiningsih Soetjiningsih ◽  
I. Made Bakta ◽  
I. Made Jawi ◽  
I. Dewa Made Sukrama ◽  
...  

The water extract of purple sweet potato contains of anthocyanin, a sub-class of flavonoid that has powerful antioxidant, antiinflammatory, and anticonvulsant effect. The aim of this study was to determine the effectiveness of supplementation of water extract of purple sweet potato towards recovery (remission) of drug resistant focal epilepsy (DRFE) in children with standard conventional antiepileptic medicine. It was found that the supplementation of purple sweet potato extract had a pure effect in improving all of the dependent variables, including decreased of the serum level of 8-OHdG by 1.611 pg/mL (p<0.001); decreased the serum level of IL-6 by 3.320 pg/mL (p<0.001); increased the total SOD serum level by 0.208 IU/mL (p=0.003); improved the EEG image (p=0.004); and decreased the seizure frequency at the end of the sixth week by 3.972 times (p<0.001), compared to the control. There is a significant effect on the use of supplementation of purple sweet potato extract in decreasing the serum level of 8-OHdG, decreasing the serum level of IL-6, increasing the total SOD serum level, improving the EEG image, decreasing the seizure frequency at the end of the sixth week, which at the end reducing the frequency of drugs resistant of focal epilepsy in children.


QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
S Ashour ◽  
A Gaber ◽  
T Hussein ◽  
A Kamal

Abstract Copyright 2019 Department of Neuropsychiatry, Ain Shams University. Unauthorized reproduction of this article is prohibited Purpose This study was designed to evaluate the therapeutic effect of low-frequency repetitive transcranial magnetic stimulation (rTMS) on patients with drug resistant focal epilepsy. Methods Fifty-five patients with drug resistant neocortical focal epilepsy were screened and 30 patients were divided into two groups (active and sham ) were given (0.5 hz , 1000 pulses , 90%of resting motor threshold (rMT)) on stimulation site detected by correlation between clinical semiology, EEG and or MRI finding. Seizures frequency, severity and seizure free days were compared for one month before and after rTMS with no change in antiepileptic drugs. We assumed 50% seizure reductionrate after rTMS. Results Seizures significantly decreased following rTMS treatment 50% seizure reduction was achieved 87.5%inthe active rTMS groupand50% in the sham rTMS group(p &gt; 0.03).in the follow-up period compared to baseline period. Seizure free days %increase in active group 20.7% compared to sham group 7.5% (p = 0.0501). Significance Low-frequency rTMS delivered into the epileptogenic zone had a significant antiepileptic effect on patients with drug resistant neocortical focal epilepsy. © 2018 Department of Neuropsychiatry, Ain Shams University


2005 ◽  
Vol 103 (4) ◽  
pp. 333-343 ◽  
Author(s):  
Massimo Cossu ◽  
Francesco Cardinale ◽  
Nadia Colombo ◽  
Roberto Mai ◽  
Lino Nobili ◽  
...  

2020 ◽  
pp. 106002802094111 ◽  
Author(s):  
Christopher T. Buckley ◽  
Olivia R. Waters ◽  
George DeMaagd

Objective: To review the pharmacology, efficacy, and safety of oral cenobamate in the treatment of uncontrolled focal epilepsy. Data Sources: The PubMed database and ClinicalTrials.gov were searched using the following terms: cenobamate, Xcopri, and YKP3089. Study Selection and Data Extraction: Articles published in English between January 2000 and April 2020 related to pharmacology, safety, and clinical trials were assessed. Data Synthesis: In a phase 2 trial, cenobamate reduced the median percentage change in seizure frequency from baseline by 56% compared with 22% for placebo ( P < 0.0001). In another phase 2 trial of multiple cenobamate doses, cenobamate reduced seizure frequency by 36% ( P = 0.0071) in the 100-mg group and 55% ( P < 0.0001) in both the 200- and 400-mg groups, compared to 24% with placebo. Adverse effects of cenobamate appear to be similar to those of other antiseizure medications and primarily affect the neurological system. Relevance to Patient Care and Clinical Practice: In patients taking antiseizure medications who continue to have focal seizures, cenobamate has efficacy at multiple doses and is generally well tolerated. Cenobamate may be distinguished from other antiseizure medications by high rates of seizure freedom not seen in previous placebo-controlled trials, which has the potential to significantly improve quality of life. However, despite this efficacy, Drug Reaction with Eosinophilia and Systemic Symptoms may remain a significant concern with cenobamate. Conclusion: As seen in clinical trials, cenobamate as an adjunctive, once-daily treatment represents an efficacious and generally well-tolerated therapy for patients with drug-resistant focal epilepsy.


2018 ◽  
Vol 13 (2) ◽  
pp. 7-19
Author(s):  
K. Yu. Mukhin ◽  
O. A. Pylaeva ◽  
M. Yu. Bobylova ◽  
N. V. Freydkova ◽  
L. Yu. Glukhova ◽  
...  

Background. Despite significant advances in epileptology, approximately one-third of epilepsy patients suffer from drug-resistant seizures. Numerous approaches are currently available to treat epilepsy; however, there are still many patients with treatment-resistant epilepsy, in whom surgical treatment is impossible and alternative methods (vagus nerve stimulation and ketogenic diet) are ineffective. Therefore, searching for novel effective antiepileptic drugs (AEDs) is crucial for these patients.Objective: analysis of own data on the efficacy and tolerability of rufinamide in patients with severe forms of epilepsy and seizures typical of Lennox–Gastaut syndrome (LGS).Materials and methods. The study included 31 patients aged between 4 and 26 years (mean age 7.5 years) that received rufinamide (inovelon). The study cohort comprised 21 males and 10 females. Fifteen patients were diagnosed with LGS, whereas 16 patients were diagnosed with structural focal epilepsy with a phenocopy of LGS. Five patients had an evolution of West syndrome to LGS. The majority of patients (n = 22) experienced predominantly axial tonic seizures and epileptic spasms that were considered as indications for introduction of rufinamide. All patients underwent electroencephalography, video-electroencephalography monitoring during wakefulness and sleep, magnetic resonance imaging (MRI) (including high-resolution MRI with special epilepsy protocols when indicated), genetic examination (tandem mass spectrometry, hereditary epilepsy gene panel test and chromosomal microarray analysis) when indicated, and laboratory tests to assess tolerability of antiepileptic drugs.Results. Good therapeutic effect (more than 50 % reduction in seizure frequency) was achieved in 14 (45.2 %) patients. A less than 50 % reduction in seizure frequency occurred in 5 (16.1 %) patients; in 2 of them seizures became shorter and milder without a significant reduction in their frequency. Rufinamide was ineffective in 9 (29 %) patients. Three (9.7 %) patients experienced aggravation (increased seizure frequency) after the introduction of rufinamide. Thus, treatment with rufinamide was effective in 19 (61.3 %) patients. Rufinamide was well tolerated by most of the patients. Side effects were observed in 6 (19 %) participants. Side effects (forced normalization) caused withdrawal of rufinamide in 1 (3.2 %) patient. Currently, 10 (32 %) patients continue to take rufinamide. Sixteen patients received rufinamide for <6 months, 17 patients – for >6 months, 5 patients – for >12 months, and 1 patient – for >2 years.Conclusion. Our findings are consistent with the results obtained by foreign authors in routine clinical practice. In our study, rufinamide was used only in patients with drug-resistant epilepsy that earlier received many of currently available AEDs (both in monotherapy and in combination with other drugs). All study participants were earlier treated with at least three different AEDs that were ineffective. Seven patients received more than 8 AEDs in various combinations. This initial drug resistance should be taken into account when analyzing the data, which can not be extrapolated to patients with unknown drug resistance. We assume that the early introduction of rufinamide (prior to the detection of drug resistance) might have yielded better results.


Sign in / Sign up

Export Citation Format

Share Document